- PD-1 Antibody (Sintilimab) Plus Histone Deacetylase Inhibitor (Chidamide) for the Treatment of Refractory or Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r ENKTL): Updates of the Phase Ib/II Scent StudyYan, Gao; Zhang, Liling; Li, Wenyu; Wei, Xu; Feng, Ru; Li, Xue-Ping; Chen, Yu; Wu, Huijing; Wang, Xiaoxiao; Bai, Bing; Huang, Huiqiang65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.
- Combination of mitoxantrone hydrochloride liposome with pegaspargase in patients with extranodal NK/T-cell lymphoma: A phase I/II clinical trialHuang, Y.; Wu, T.; Hu, Y.; Li, Y.; Ma, J.; Guo, Y.; Zhou, H.; Yang, R.; Gong, Y.; Zhang, Q. Y.; Lin, L. E.; Zhou, R.; Liu, Y.; Pan, Z.; Xue, J.; Wang, D.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 2022-09-09 To 2022-09-13.
- Orelabrutinib Plus R-CHOP Regimen in Treatment-Naive Patients with TP53-Mutated Diffuse Large B-Cell Lymphoma (DLBCL)Xiao, Yi; Wu, Jiaying; Zhou, Mi; Shang, Zhen; Zhu, Ming65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.
会议论文
Sintilimab Plus P-Gemox (Pegaspargase, Gemcitabine and Oxaliplatin) Regimen for Newly-Diagnosed Advanced, Extranodal Natural Killer/T Cell Lymphoma, Nasal Type: A Multicenter, Phase 2 Cohort of the Open-Label Spirit Study
3被引23阅读
